The clinical application of monoclonal antibodies in chronic lymphocytic leukemia

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

(2010) J. S. CROWE et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Differential effects of IL-2 and IL-21 on expansion of the CD4+CD25+Foxp3+T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia

(2010) Aruna Gowda et al.   mAbs

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

(2009) Apostolia-Maria Tsimberidou et al.   CANCER

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

(2009) Stephan Stilgenbauer et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma

(2009) J A Woyach et al.   LEUKEMIA

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901

(2009) John C. Byrd et al.   LEUKEMIA & LYMPHOMA

Functional Analysis of a Dominant Negative Mutation of Interferon Regulatory Factor 5

(2009) Long Yang et al.   PLoS One

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

(2008) K. I. Lin et al.   BLOOD

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro

(2008) A. Gowda et al.   BLOOD

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

(2008) John D. Hainsworth et al.   CANCER

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   CANCER

Disease-Specific Complications of Chronic Lymphocytic Leukemia

(2008) C. Dearden   Hematology-American Society of Hematology Education Program